Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel launches VEPPANU for advanced breast cancer at $29,400 per month in the US.

What the company is saying

Rigel Pharmaceuticals announces the immediate US commercial availability of VEPPANU (vepdegestrant) for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, priced at $29,400 per 30-day supply. The company frames VEPPANU as the first and only FDA-approved PROTAC, emphasizing its novelty and potential to become an important new treatment option. Messaging highlights Rigel’s established oncology infrastructure, experienced teams, and comprehensive patient support programs as factors positioning the company for a successful launch and long-term growth. The announcement stresses the product’s clinical differentiation and access through specialty distributors and pharmacies in both the United States and Puerto Rico. Rigel also notes an exclusive global license agreement with Arvinas, Inc. and Pfizer Inc. for VEPPANU’s development and commercialization. The tone is confident and positive, focusing on anticipated impact and readiness, while operational and financial specifics are downplayed or omitted.

What the data suggests

The announcement provides clear confirmation that VEPPANU is available by prescription in the United States and Puerto Rico for a defined subset of breast cancer patients, with a set price of $29,400 per month. Clinical safety data is disclosed: serious adverse reactions occurred in 9% of patients, with fatal adverse reactions in 1.0%, permanent discontinuation in 2.9%, dosage interruptions in 14%, and reductions in 1.9%. The recommended dose is 200 mg orally once daily. The company claims statistically significant and clinically meaningful improvement in progression-free survival versus fulvestrant, but no numerical efficacy results or comparative data are provided. No financial performance data, revenue projections, or uptake metrics are disclosed, leaving the commercial impact unquantified. The majority (70%) of breast cancer cases are ER+/HER2-, and up to 50% of patients treated with endocrine therapy and a CDK4/6 inhibitor acquire ESR1 mutations, defining the target market but not its size or expected penetration. The data is sufficient to confirm product launch and safety profile, but insufficient for financial or commercial analysis.

Analysis

The announcement is generally positive in tone, highlighting the commercial launch of VEPPANU in the United States following FDA approval. The core realised claims—product availability, pricing, and some clinical safety data—are supported by specific disclosures. However, the narrative inflates the signal by emphasizing the product's 'potential' as an important new treatment option and the company's readiness to execute a successful launch, without providing any financial metrics (revenue, profit, cash flow) or quantitative evidence of commercial uptake. The forward-looking claims about long-term growth and market impact are not substantiated by measurable data. There is no evidence of a large capital outlay paired with long-dated returns; the product is already available. The gap between narrative and evidence is moderate: the launch is real, but the investment case cannot be assessed for profitability or sustainability due to missing financial disclosures.

Risk flags

• ●There is no disclosure of expected or actual sales figures, revenue guidance, or uptake metrics for VEPPANU, making it impossible to assess the product’s commercial potential or financial impact. This lack of transparency limits investors’ ability to gauge profitability or sustainability.
• ●Efficacy claims are made without supporting numerical data from clinical trials, such as progression-free survival rates or hazard ratios versus fulvestrant. This omission prevents independent validation of the product’s clinical advantage and market differentiation.
• ●Safety data shows that 9% of patients experienced serious adverse reactions and 1.0% experienced fatal adverse reactions, which could limit adoption or trigger payer or prescriber caution. The impact of these safety signals on real-world use is not addressed.
• ●Forward-looking statements about long-term growth and successful launch are not backed by operational or financial evidence, increasing the risk that actual results may fall short of management’s narrative.

Bottom line

Rigel’s launch of VEPPANU marks a real commercial milestone, with immediate US availability and a premium price point for a targeted breast cancer population. The company’s confident narrative about clinical impact and market readiness is not matched by disclosure of sales expectations, financial projections, or detailed efficacy data. Investors cannot assess the scale or profitability of this launch from the information provided. The most important takeaway is that while the product is now on the market, the investment case remains unquantified until Rigel discloses uptake, revenue, and margin data. For now, the announcement signals potential but lacks actionable financial substance.

Announcement summary

(NASDAQ:RIGL) Rigel Pharmaceuticals, Inc. announced that VEPPANU TM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC), as detected by a U.S. Food and Drug Administration (FDA)-authorized test, with disease progression following at least one line of endocrine therapy. VEPPANU is the first and only FDA-approved PROTAC and is available through Rigel's network of specialty distributors and specialty pharmacies in the United States and Puerto Rico at $29,400 per 30-day supply. In May 2026, Rigel announced it entered into an exclusive, global license agreement with Arvinas, Inc. and Pfizer Inc. to develop, manufacture and commercialize VEPPANU. The recommended dosage of VEPPANU is 200 mg taken orally once daily. In a pivotal trial, VEPPANU was generally well tolerated and demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus fulvestrant in this patient population. Serious adverse reactions occurred in 9% of patients who received VEPPANU, and fatal adverse reactions occurred in 1.0% of patients who received VEPPANU. Permanent discontinuation of VEPPANU due to an adverse reaction occurred in 2.9% of patients, dosage interruptions occurred in 14% of patients, and dosage reductions occurred in 1.9% of patients.

Disagree with this article?